Gain Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gene Mack
- Full Time Employees
- 23
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4800 Montgomery Lane Bethesda MD United States of America 20814
- IPO Date
- Mar 19, 2021
- CIK
- 0001819411
- Website
- gaintherapeutics.com
- Similar Companies
- Business
- Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation allosteric small molecule therapeutics to treat diseases with high unmet medical needs, including neurodegenerative disorders, lysosomal storage disorders, metabolic disorders, and oncology. Founded in 2017 and headquartered in Bethesda, Maryland, the company operates in the United States, Switzerland, Spain, and Australia. Its proprietary drug discovery platform, Magellan™, leverages artificial intelligence, 3D structural biology, and physics-based modeling to identify novel allosteric binding sites on disease-implicated proteins and develop small molecule regulators that modulate protein function to address the underlying causes of disease. Gain Therapeutics’ lead product candidate, GT-02287, is an orally administered, brain-penetrant allosteric regulator of glucocerebrosidase (GCase) designed to treat GBA1 Parkinson’s disease and other neurodegenerative diseases by restoring enzyme function and reducing toxic substrates, currently undergoing a Phase 1b clinical trial with positive early safety, tolerability, and biomarker data. The company is developing additional candidates targeting disorders such as dementia with Lewy bodies, Alzheimer's disease, Gaucher’s disease, and other lysosomal and metabolic disorders. Recent major developments include the successful completion of a public offering raising approximately $7.1 million, the initiation and early positive data reporting of the Phase 1b extension study for GT-02287 allowing longer dosing duration, presentations at major scientific conferences including Neuroscience 2025, and advances in its AI-driven drug discovery capabilities. Gain Therapeutics continues to focus on expanding its pipeline and advancing clinical programs while leveraging its innovative technology platform to address a broad range of protein function-mediated diseases.
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference
Gain Therapeutics to Present at the 38th Annual ROTH Conference
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% – What’s Next?
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of “Moderate Buy” from Analysts
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know